Daiichi Sankyo and AstraZeneca announced that the European Medicines Agency, or EMA, has validated the Type II Variation application for Enhertu as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 low or HER2 ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca announces approval for Imfinzi combination
- Healthcare Stocks Rise despite Medicare Price Cuts for Their Drugs
- Biden administration announces lower prices for 10 Medicare drugs in 2026
- AstraZeneca: IMFINZI gets priority review and BTD to treat LS-SCLC patients
- U.S. to announce prices for drugs in Medicare negotiations, NY Times says